Table 1: FluQuadri Ingredients Quantity (per dose) Ingredient FluQuadri Junior FluQuadri 0.25 mL Dose 0.5 mL Dose Active Substance: Influenza virus µg µg 30 HA 60 HA total haemagglutinina: A (H1N1) µg µg 7.5 HA 15 HA A (H3N2) µg µg 7.5 HA 15 HA B (Victoria lineage) µg µg 7.5 HA 15 HA B (Yamagata lineage) µg µg 7.5 HA 15 HA Sodium chloride µg µg 2.2 4.4 Sodium phosphate dibasic anhydrous µg µg 165.8 331.5 Sodium phosphate monobasic anhydrous µg µg 50 100 Water for injections Up to 0.25 mL Up to 0.5 mL Formaldehyde µg µg 50 100 ≤ ≤ Octoxinol 9 µg µg 125 250 ≤ ≤ Ovalbumin µg µg 0.5 1 ≤ ≤ Preservative None None aper AIVC and WHO recommendations PHARMACOLOGY Mechanism of action FluQuadri provides active immunisation against the four influenza virus strains (two A subtypes and two B strains) contained in the vaccine. FluQuadri induces humoral antibodies against the haemagglutinins. Specific levels of haemagglutination-inhibition (HI) antibody titre vaccination with inactivated influenza virus vaccines have not been correlated with protection from influenza illness, but HI antibody titres have been used as a measure of vaccine activity. In some human challenge studies, HI antibody titres of 1:40 have been associated with protection ≥ from influenza illness in up to 50% of participants. HI antibody titres 1:40 are generally ≥ obtained within 3 to 4 weeks. Annual influenza is recommended as immunity declines during the year after vaccination and because circulating strains of influenza virus may change from year to year.
Table 1: FluQuadri Ingredients Ingredient Quantity (per dose) FluQuadri Junior 0.25 mL Dose FluQuadri 0.5 mL Dose Active Substance: Influenza virus haemagglutinina: 30 µg HA 60 µg HA total A (H1N1) 7.5 µg HA 15 µg HA A (H3N2) 7.5 µg HA 15 µg HA B (Victoria lineage) 7.5 µg HA 15 µg HA B (Yamagata lineage) 7.5 µg HA 15 µg HA Sodium chloride 2.2 µg 4.4 µg Sodium phosphate dibasic anhydrous 165.8 µg 331.5 µg Sodium phosphate monobasic anhydrous 50 µg 100 µg Water for injections Up to 0.25 mL Up to 0.5 mL Formaldehyde ≤ 50 µg ≤ 100 µg Octoxinol 9 ≤ 125 µg ≤ 250 µg Ovalbumin ≤ 0.5 µg ≤ 1 µg Preservative None None aper AIVC and WHO recommendations PHARMACOLOGY Mechanism of action FluQuadri provides active immunisation against the four influenza virus strains (two A subtypes and two B strains) contained in the vaccine. FluQuadri induces humoral antibodies against the haemagglutinins. Specific levels of haemagglutination-inhibition (HI) antibody titre with inactivated influenza virus vaccines have not been correlated with protection from influenza illness, but HI antibody titres have been used as a measure of vaccine activity. In some human challenge studies, HI antibody titres of ≥ 1:40 have been associated with protection from influenza illness in up to 50% of participants. HI antibody titres ≥ 1:40 are generally obtained within 3 to 4 weeks. Annual influenza vaccination is recommended as immunity declines during the year after vaccination and because circulating strains of influenza virus may change from year to year.
auspar-influenza-virus-haemagglutinin-150206-pi.docx